Chromophare F300
Payments companies reported to CMS as associated with Chromophare F300. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Chromophare F300, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Chromophare F300
These are the largest totals companies reported as associated with Chromophare F300. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Anthony Calabretta | Wooster, OH | Surgery | $2,684.38 |
| Brian Mcgrath | Buffalo, NY | Orthopaedic Surgery | $2,068.59 |
| Ryan Black | Gillette, WY | Otolaryngology | $2,057.02 |
| Victor Bautista-Hernandez | San Antonio, TX | Thoracic Surgery (Cardiothoracic Vascular Surgery) | $1,780.08 |
| Joshua Hornig | Charleston, SC | Otolaryngology | $1,726.48 |
| Louis Kavoussi | New Hyde Park, NY | Urology | $1,678.16 |
| Samuel Navon | Gillette, WY | Ophthalmology | $1,664.99 |
| Jeffrey Henning | Wenatchee, WA | Orthopaedic Surgery | $1,619.60 |
| Van Hien Tran | Houston, TX | Surgery | $1,618.11 |
| Tiffany Griffin | Jackson, MS | Psychiatric/Mental Health (Nurse Practitioner) | $1,494.01 |
Prescribed Chromophare F300?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.